Drugs / RLD2102
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06518122 | Sep 2024 → Jan 2025 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT06357910 | May → Jul 2024 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT06346184 | May → Jun 2024 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT05155995 | Sep 2021 → Nov 2022 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RLD2102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05155995 ↗ |